source
- Verdiva ends mid-stage study of oral GLP-1 amid ‘market evolution’The candidate is an oral version of ecnoglutide, a subcutaneous formulation of which is approved in China for type 2 diabetes and weight management. Pfizer owns commercialization rights for ecnoglu…BioSpace · 1mo ago↗ source
- Roche signs $1 billion deal with China’s Rona Therapeutics for RNAi obesity drugRoche announced a new agreement with Chinese biotech Rona Therapeutics to acquire an experimental RNA interference therapy targeting the protein ALK7 for obesity. Under the terms, Roche will pay $…